PowerVision focuses on creating fluid-based intraocular lens implants. Credit: Gordon Wrigley.

Alcon has acquired US-based medical device development company PowerVision in a $285m deal.

PowerVision focuses on creating fluid-based intraocular lens implants. Under the agreement, Alcon will make payments for specified regulatory and commercial milestones that are achieved from 2023.

The acquisition demonstrates Alcon’s proposal to drive growth and innovation in advanced technology intraocular lenses (AT-IOLS) to address the needs of cataract surgery patients worldwide.

“This intraocular lens may be the preferred IOL for cataract surgery patients who desire spectacle independence.”

Alcon Global Business and Innovation president Michael Onuscheck said: “As the industry leader in cataract surgery, we’re eager to accelerate development of this potentially breakthrough accommodating lens technology.

“By treating cataracts and restoring natural, continuous range of vision, this intraocular lens may be the preferred IOL for cataract surgery patients who desire spectacle independence.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

PowerVision president and CEO and co-founder Barry Cheskin said: “We’re thrilled to officially join Alcon and its pioneering history of launching new innovation in the field of ophthalmology.

“We look forward to bringing this innovative IOL technology to eyecare providers and customers in the years ahead.”

Cataracts is one of the most common age-related eye conditions and the leading cause of preventable blindness in adults aged 55 and older in the US. It can be hereditary and congenital.

In December last year, Alcon acquired Tear Film Innovations, which focusses on developing medical products to treat various eye disorders.